MicroPort CardioFlow Medtech Corporation provided earnings guidance for the six months ended June 30, 2021. for the six months, the company expected to record a net loss (unaudited) of approximately RMB 68 million to RMB 73 million for the six months ended June 30, 2021, representing a decrease of approximately 40% to 44% from that of approximately RMB 122 million. The expected decrease in the net loss of the Group is mainly attributable to (i) the significant increase in revenue as a result of the significant progress the Group has made in commercializing TM VitaFlow; (ii) the significant increase in gross profit due to the effective cost control in line with the revenue growth; and (iii) the decrease in finance costs and other operating costs as certain cost items recorded in the six months ended June 30, 2020 were one-off and non-recurring in nature. As TM of June 30, 2021, TAVI (transcatheter aortic heart valve implantation) procedures using VitaFlow had been performed at over 200 hospitals in China, most of which are Class IIIA Hospitals located at tier-one and tier-two cities.